SARS-CoV-2: What is known and what there is to know-Focus on coagulation and lipids

Eur J Clin Invest. 2020 Jul;50(7):e13311. doi: 10.1111/eci.13311. Epub 2020 Jun 25.

Authors

Federico Carbone^{1

2}, Fabrizio Montecucco^{2

3}, Marcel Twickler⁴

Affiliations

¹ First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
² IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.
³ First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy.
⁴ Department of Endocrinology, Diabetology and Metabolic Diseases, Faculty of Medicine and Health Sciences, Deurne/Antwerp University of Antwerp, Antwerp, Belgium.

No abstract available

Publication types

Editorial

MeSH terms

Anticoagulants / therapeutic use
Betacoronavirus
Blood Coagulation Disorders / blood*
Blood Coagulation Disorders / drug therapy
Blood Coagulation Disorders / metabolism
COVID-19
Coronavirus Infections / blood*
Coronavirus Infections / metabolism
Disseminated Intravascular Coagulation / blood
Disseminated Intravascular Coagulation / drug therapy
Disseminated Intravascular Coagulation / metabolism
Endothelium, Vascular / metabolism
Fibrin Fibrinogen Degradation Products / metabolism
Heparin / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Lipid Metabolism
Pandemics
Pneumonia, Viral / blood*
Pneumonia, Viral / metabolism
Prothrombin Time
Pulmonary Embolism / blood
Pulmonary Embolism / drug therapy
Pulmonary Embolism / metabolism
SARS-CoV-2
Thrombocytopenia / blood
Thrombocytopenia / metabolism
Thrombotic Microangiopathies / blood*
Thrombotic Microangiopathies / drug therapy
Thrombotic Microangiopathies / metabolism
Triglycerides / metabolism
Venous Thromboembolism / blood*
Venous Thromboembolism / drug therapy
Venous Thromboembolism / metabolism

Substances

Anticoagulants
Fibrin Fibrinogen Degradation Products
Heparin, Low-Molecular-Weight
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Triglycerides
fibrin fragment D
Heparin

Grants and funding